What is retatrutide?
The 2023 primary phase 2 paper describes retatrutide as an agonist of GIP, GLP-1 and glucagon receptors. These are the targets behind its triple-receptor description; they do not demonstrate the effects of this supplier vial. Retatrutide phase 2 trial.
The catalogue offers 10mg / 20mg / 30mg / 40mg vial variants. These are separate listed amounts, not a concentration or clinical schedule. A receptor description does not establish that a supplier presentation matches the investigational material. Retatrutide phase 2 trial.
Retatrutide weight-loss results: 2023 phase 2 trial
The 2023 trial enrolled 338 adults and used percentage change in body weight at 24 weeks as its primary endpoint. Retatrutide phase 2 trial.
Participants had a body-mass index (BMI) of at least 30, or a BMI from 27 to below 30 plus at least one weight-related condition. At 24 weeks, the least-squares mean changes in body weight ranged from -7.2% to -17.5% across the reported retatrutide groups, compared with -1.6% in the placebo group. These are historical trial-group results, not expected outcomes for the catalogue vial. Retatrutide phase 2 trial.
The range describes the different groups' reported least-squares means. It is not a range of individual responses, a single pooled retatrutide estimate or a placebo-subtracted difference. Retatrutide phase 2 trial.
Side effects in the 2023 retatrutide trial
Gastrointestinal events were the most common adverse events in the retatrutide groups. The trial also observed heart-rate increases that peaked at 24 weeks and then declined. Retatrutide phase 2 trial.
Is retatrutide FDA approved?
FDA's US GLP-1 communication states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. It also identifies retatrutide marketing as an unapproved-drug concern. These are US FDA statements, not a worldwide or Thai approval assessment. FDA retatrutide status communication.
The 2023 phase 2 trial reports investigational clinical evidence; the FDA statement describes US regulatory status. Neither establishes efficacy, safety or authenticity for this supplier vial. Retatrutide phase 2 trial, FDA retatrutide status communication.
Retatrutide vial, pen and related medicines
For a distinct GLP-1-related medicine topic, see tirzepatide. The Retatrutide Pen instead provides a comparison of catalogue presentation. These are related research and format links, not a head-to-head result or evidence of superiority. Retatrutide phase 2 trial.
